Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03753087
Other study ID # 2018-9-25
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 16, 2019
Est. completion date January 10, 2022

Study information

Verified date January 2022
Source National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients enrolled into the study will be randomly allocated either to Empagliflozin group or control group. In the Empagliflozin group patients will be receiving standard care + Empagliflozin 10 mg o.d., in the control group patients will be receiving standard care without sodium glucose contransporter 2 (SGLT2) inhibitors.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date January 10, 2022
Est. primary completion date December 16, 2021
Accepts healthy volunteers No
Gender All
Age group 45 Years to 80 Years
Eligibility Inclusion Criteria: 1. Males and females aged 45 to 80 years at screening 2. Diagnosis of type-2 diabetes mellitus with stable glucose-lowering background therapy for at least 12 weeks 3. HbA1c = 6,5% and = 10% at screening 4. Diagnosis of HFpEF which includes: - Symptoms ± signs (as defined in 2016 European Society of Cardiology guidelines for the diagnosis and treatment of acute and chronic heart failure) - Ejection fraction = 50% (by Simpson) - Increased LV filling pressures at rest or during exercise determined by echocardiography (LV diastolic dysfunction grade II/III and/or positive diastolic stress test) [according to American Society of Echocardiography and European Association of Cardiovascular Imaging (ASE/EACVI) Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography, 2016] 5. Signed and dated informed consent Exclusion Criteria: 1. Pretreatment with empagliflozin or other SGLT-2 inhibitor within the last 2 months 2. Type-1 diabetes mellitus 3. NYHA classification IV or acute decompensated heart failure at screening 4. Impaired renal function, defined as eGFR <30 ml/min/1.73 m² of body-surface-area (CKD-EPI) 5. Systolic blood pressure > 180 mmHg or < 90 mmHg 6. Permanent atrial flutter or atrial fibrillation 7. Other conditions that may be responsible for impaired diastolic function such as hypertrophic/restrictive cardiomyopathy, constrictive pericarditis and etc. 8. Anemia (Hb < 100 g/l) 9. Myocardial infarction, coronary artery bypass graft surgery within the last 3 months 10. Stroke or TIA within the last 3 months 11. Indications of liver disease 12. Acute genital infection or urinary tract infection 13. Pregnancy 14. Additional exclusion criteria may apply

Study Design


Intervention

Drug:
Empagliflozin
10 mg tablet
Other:
Standard care
Standard care with no SGLT-2 inhibitors

Locations

Country Name City State
Russian Federation National Medical Research Center for Cardiology Moscow

Sponsors (2)

Lead Sponsor Collaborator
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Ministry of Health of the Russian Federation

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in 6-minute walking distance (6MWD) Difference in distance walked during 6-minute walking test (6MWT) between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in left ventricular mass index (LVMI) Difference in LVMI assessed by echocardiography between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in left atrial volume index (LAVI) Difference in LAVI assessed by echocardiography between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in left atrial stiffness Difference in left atrial stiffness assessed as a ratio of mitral E/e' ratio to left atrial strain s between 24 weeks after baseline and at baseline 24 weeks
Secondary Change estimated pulmonary artery systolic pressure (PASP) Difference in PASP assessed by echocardiography both at rest and during diastolic stress test (DST) between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in average e' velocity Difference in average e' velocity assessed by echocardiography both at rest and during diastolic stress test (DST) between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in average E/e' ratio Difference in average E/e' ratio assessed by echocardiography both at rest and during diastolic stress between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in N-terminal pro b-type natriuretic peptide (NT-proBNP) Difference in NT-proBNP plasma levels between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in Cyclic guanosine monophosphate (cGMP) Difference in cGMP plasma levels between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in Endothelin 1 (ET-1) Difference in ET-1 plasma levels between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in Growth/differentiation factor 15 (GDF-15) Difference in GDF-15 plasma levels between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in ST2 Difference in ST2 plasma levels between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in Galectin-3 Difference in Galectin-3 plasma levels between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in carboxyterminal propeptide of type I collagen (PICP) Difference in PICP plasma levels between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in Human Pentraxin 3 (PTX3) Difference in PTX3 plasma levels between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in high-sensitivity C-reactive protein (hsCRP) Difference in hsCRP plasma levels between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in Interleukin-6 (IL-6) Difference in IL-6 plasma levels between 24 weeks after baseline and at baseline 24 weeks
Secondary Change of New York Heart Association (NYHA) functional classification Difference in NYHA class between 24 weeks after baseline and at baseline 24 weeks
Secondary Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) score Difference in MLHFQ score between 24 weeks after baseline and at baseline.
The questionnaire is comprised of 21 important physical, emotional and socioeconomic ways heart failure can adversely affect a patient's life. After receiving brief standardized instructions, the patient marks a 0 (zero) to 5 scale to indicate how much each itemized adverse of heart failure has prevented the patient from living as he or she wanted to live during the past 4 weeks. The questionnaire is simply scored by summation of all 21 responses.
Score ranges from 0 (best quality of life) to 105 (worst quality of life).
24 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2